STOK – stoke therapeutics, inc. (US:NASDAQ)

DELAYED


Volume Shares
1 Day Range
Volume Ratio
52 Week High
52 Week Low


VWAP
Today’s Volatility
20 Day Volatility
Open
Prior Close

YTD

1 Day

STOK

SPY

QQQ

Swipe to see more

Main News & Impact Reports

Date

Time

Symbol

Headline

Impact

2/5

05:03 am

stok

Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.

Medium Report

Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.

Report

2/5

05:03 am

stok

Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.

Medium Report

Stoke Therapeutics (NASDAQ:STOK) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.

Report

2/5

04:55 am

stok

Stoke Therapeutics initiated with a Buy at Guggenheim

Medium Report

Stoke Therapeutics initiated with a Buy at Guggenheim

Report

2/5

04:55 am

stok

Stoke Therapeutics initiated with a Buy at Guggenheim

Medium Report

Stoke Therapeutics initiated with a Buy at Guggenheim

Report

1/12

08:51 am

stok

Rating for STOK

Medium Report

Rating for STOK

Report

1/12

08:51 am

stok

Rating for STOK

Medium Report

Rating for STOK

Report

1/5

08:22 am

stok

Rating for STOK

Medium Report

Rating for STOK

Report

1/5

07:09 am

stok

Rating for STOK

Medium Report

Rating for STOK

Report

11/21

05:31 am

stok

Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.

Medium Report

Stoke Therapeutics (NASDAQ:STOK) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.

Report

In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.